The Influence of Cost-Effectiveness Evaluations on Reimbursement in Australia: A Retrospective Study of Decisions made by the Pharmaceutical Benefits Advisory Committee-Reference-Cited by-同舟云学术

The Influence of Cost-Effectiveness Evaluations on Reimbursement in Australia: A Retrospective Study of Decisions made by the Pharmaceutical Benefits Advisory Committee

Published:2014-08 Issue:4 Volume:28 Page:187-193
ISSN:1178-2595
Container-title:Pharmaceutical Medicine
language:en
Short-container-title:Pharm Med

Author:

Ngo Phuong

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40290-014-0063-5.pdf

Reference20 articles.

1. Wonder MJ, Neville AM, Parsons R. Are Australians able to access new medicines on the Pharmaceutical Benefits Scheme in a more or less timely manner? An analysis of Pharmaceutical Benefits Advisory Committee recommendations, 1999–2003. Value Health. 2006;9:205–12.

2. Henry DA, Hill SR, Harris A. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme. JAMA. 2005;294:2630–2.

3. Duckett SJ. Drug policy down under: Australia’s Pharmaceutical Benefits Scheme. Health Care Financ Rev. 2004;25:55.

4. Aristides M, Mitchell A. Applying the Australian guidelines for the reimbursement of pharmaceuticals. Pharmacoeconomics. 1994;6:196–201.

5. Stephen JM, Handke B, Doshi JA, et al. International survey of methods used in health technology assessment (HTA): does practice meet the principles proposed for good research? Comp Effectiveness Res. 2012;2:29–44.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors associated with Pharmaceutical Benefits Advisory Committee decisions for listing medicines for diabetes and its associated complications;Australian Health Review;2022-12-22

2. Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs;ESMO Open;2022-10

3. Appraising Drugs Based on Cost-effectiveness and Severity of Disease in Norwegian Drug Coverage Decisions;JAMA Network Open;2022-06-29

4. Quality of health economic evaluations submitted to the Italian Medicines Agency: current state and future actions;International Journal of Technology Assessment in Health Care;2020-09-10

5. A flexible formula for incorporating distributive concerns into cost-effectiveness analyses: Priority weights;PLOS ONE;2019-10-10